AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34111564 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-naive
Number of subjects: 30
Study 34111564 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-RIPC
Number of subjects: 30
Study 35147087 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-press needle (EPN) treatment, 3 sessions per week for 6 weeks (total of 18 sessions)
Number of subjects: 122
Study 35147087 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention for the first 6 weeks)
Number of subjects: 122
Study 35147087 — intervention group
Group type: EXPERIMENTAL
Intervention: EPN treatment
Number of subjects: 122
Study 34019214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOXIRI plus bevacizumab (irinotecan 200 mg/m2, oxaliplatin 100 mg/m2, capecitabine 1600 mg/m2, bevacizumab 7.5 mg/kg)
Number of subjects: 9
Study 34019214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOXIRI plus bevacizumab (irinotecan 200 mg/m2, oxaliplatin 130 mg/m2, capecitabine 1600 mg/m2, bevacizumab 7.5 mg/kg)
Number of subjects: 9
Study 34019214 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients receiving CAPOXIRI plus bevacizumab
Number of subjects: 9
Study 33086291 — intervention group
Group type: EXPERIMENTAL
Intervention: Central topography (CT) from IOLMaster 700
Number of subjects: 105
Study 33086291 — intervention group
Group type: COMPARATOR
Intervention: Predicate topographic maps (PT) from a Placido‐dual‐Scheimpflug tomographer
Number of subjects: 105
Study 35412495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hydration (IH) with Ringer's Lactate at a rate of 3 mL/kg/h during and for 8 h following the procedure, plus an additional bolus of 20 mL/kg at the end of the procedure.
Number of subjects: 155
Study 35412495 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration (SH) with Ringer's Lactate at a rate of 1.5 mL/kg/h during and for 8 h following the procedure.
Number of subjects: 155
Study 35412495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hydration (IH) with Ringer's Lactate.
Number of subjects: 155
Study 35412495 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration (SH) with Ringer's Lactate.
Number of subjects: 155
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy® (n = 36)
Number of subjects: 142
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR; n = 37)
Number of subjects: 142
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Cards (DC; n = 35)
Number of subjects: 142
Study 33485746 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 34)
Number of subjects: 142
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 142
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 142
Study 33485746 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Cards (DC)
Number of subjects: 142
Study 33485746 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 32860041 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (ACS)
Number of subjects: 751
Study 32860041 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (ACS)
Number of subjects: 751
Study 32860041 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (CCS)
Number of subjects: 751
Study 32860041 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (CCS)
Number of subjects: 751
Study 35347756 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized weighted combination test
Number of subjects: 0
Study 35347756 — intervention group
Group type: COMPARATOR
Intervention: Stage 1 data
Number of subjects: 0
Study 35347756 — intervention group
Group type: COMPARATOR
Intervention: Stage 2 data
Number of subjects: 0
Study 35347756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation approach
Number of subjects: 0
Study 35347756 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation methods
Number of subjects: 0
Study 35347756 — intervention group
Group type: EXPERIMENTAL
Intervention: Data example
Number of subjects: 0
Study 33650980 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mindfulness program
Number of subjects: 19
Study 33972458 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 2643
Study 33972458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Approach (SR+CA)
Number of subjects: 2643
Study 33972458 — intervention group
Group type: COMPARATOR
Intervention: Stent Retriever (SR)
Number of subjects: 2643
Study 34742029 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training
Number of subjects: 35
Study 34742029 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 35
Study 34742029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BFR and non-BFR)
Number of subjects: 35
Study 35909888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillatory expectoration system (HFCWO)
Number of subjects: 65
Study 35909888 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 65
Study 33298127 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended online and human behavioural therapy for tics
Number of subjects: 51
Study 33298127 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital technology for trial procedures
Number of subjects: 51
Study 33298127 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly trained and motivated trial staff
Number of subjects: 51
Study 33298127 — intervention group
Group type: COMPARATOR
Intervention: Comparison with 51 trials conducted between 2010 and 2020
Number of subjects: 51
Study 35972369 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 176
Study 33326316 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRPT vaccine (administered as a 6, 10, 14 week primary series with a toddler booster at 15-18 months)
Number of subjects: 64
Study 33326316 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRPT vaccine
Number of subjects: 64
Study 32352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically assessed MSE refractive error (per-unit increase in D)
Number of subjects: 405692
Study 32352494 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-D decrease in MSE refractive error
Number of subjects: 405692
Study 32352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically assessed IOP (per-unit increase in mm Hg)
Number of subjects: 405692
Study 616475925 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (160 mg i.v.)
Number of subjects: 10
Study 616475925 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg p.o.) plus Furosemide
Number of subjects: 10
Study 35749512 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic motor-imagery training (KMI)
Number of subjects: 0
Study 35749512 — intervention group
Group type: COMPARATOR
Intervention: Static visual imagery training (SVI)
Number of subjects: 0
Study 32703720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D oral pill (100,000 IU)
Number of subjects: 62
Study 32703720 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin oil application (SOA) plus vitamin D3 suspension with essential oil enhancer
Number of subjects: 62
Study 32703720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pill, oral liquid, SOA)
Number of subjects: 62
Study 32879767 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS spectacle lenses (n = 79)
Number of subjects: 160
Study 32879767 — intervention group
Group type: COMPARATOR
Intervention: SV spectacle lenses (n = 81)
Number of subjects: 160
Study 34773606 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg once daily
Number of subjects: 5734
Study 34773606 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg once daily
Number of subjects: 5734
Study 34773606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study 32379637 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation training for 6 weeks
Number of subjects: 72
Study 32379637 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation intervention (Control)
Number of subjects: 72
Study 33753428 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoPACT (structured six-session couples counselling intervention)
Number of subjects: 300
Study 33753428 — intervention group
Group type: COMPARATOR
Intervention: LifeSteps (three-session individually-delivered HIV adherence counselling intervention)
Number of subjects: 300
Study 34623638 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (vincristine, dactinomycin, and cyclophosphamide)
Number of subjects: 0
Study 34623638 — intervention group
Group type: COMPARATOR
Intervention: VAC/VI (VAC alternating with vincristine plus irinotecan)
Number of subjects: 0
Study 34347815 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime noise pollution levels measured in dBA (Leq, 5-min)
Number of subjects: 75
Study 34347815 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise land-use regression model
Number of subjects: 75
Study 34347815 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation model of noise land-use regression
Number of subjects: 75
Study 34347815 — intervention group
Group type: EXPERIMENTAL
Intervention: Community per capita income
Number of subjects: 75
Study 34347815 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted daytime noise levels
Number of subjects: 75
Study 33217785 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m2
Number of subjects: 1334
Study 32114889 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (Q2W dose)
Number of subjects: 7690
Study 32114889 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (monthly dose)
Number of subjects: 7690
Study 32114889 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 7690
Study 33814182 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol treatment
Number of subjects: 100
Study 33814182 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (excision and primary closure)
Number of subjects: 100
Study 33814182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 34028808 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% simvastatin/2% cholesterol cream applied twice daily
Number of subjects: 8
Study 34028808 — intervention group
Group type: COMPARATOR
Intervention: Bland emollients
Number of subjects: 8
Study 32569854 — intervention group
Group type: EXPERIMENTAL
Intervention: Active imagery rescripting (ImRs-A)
Number of subjects: 100
Study 32569854 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive imagery rescripting (ImRs-P)
Number of subjects: 100
Study 32569854 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal (IRE)
Number of subjects: 100
Study 32569854 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (NIC)
Number of subjects: 100
Study 35583280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C
Number of subjects: 0
Study 35583280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C with chemotherapy
Number of subjects: 0
Study 34221603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30
Study 33337797 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4-rocuronium
Number of subjects: 280
Study 33337797 — intervention group
Group type: COMPARATOR
Intervention: Saline-succinylcholine
Number of subjects: 280
Study 34542059 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar PRF
Number of subjects: 66
Study 34542059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar PRF
Number of subjects: 66
Study 32720988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya virus-like particle vaccine
Number of subjects: 0
Study 32720988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35459183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred post-stroke hospital/home transition programme combining telephonic support by a trained case manager and access to an interactive Internet information platform for 12 months.
Number of subjects: 170
Study 35459183 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 170
Study 35459183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred post-stroke hospital/home transition programme.
Number of subjects: 170
Study 33980233 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care use
Number of subjects: 3727
Study 33980233 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery care use
Number of subjects: 3727
Study 33980233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal care use
Number of subjects: 3727
Study 36018222 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged cumulative blood pressure (cumBP)
Number of subjects: 3330
Study 36018222 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone treatment
Number of subjects: 3330
Study 34338714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride, 20 mg daily for 26 weeks
Number of subjects: 1221
Study 34338714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1221
Study 35131634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 21
Study 33837906 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (500 mL) plus standard drugs
Number of subjects: 62
Study 33837906 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 62
Study 34482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious Coping Scale
Number of subjects: 514
Study 34482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Religious Coping subscale
Number of subjects: 514
Study 34482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Religious Coping subscale
Number of subjects: 514
Study 34482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative religious coping in male adolescents aged 15-17
Number of subjects: 514
Study 34042299 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 21
Study 34042299 — intervention group
Group type: COMPARATOR
Intervention: Normal eating (NE)
Number of subjects: 21
Study 35202009 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (WBF) and probiotic Bifidobacterium animalis subsp. lactis GCL2505 (PB GCL2505)
Number of subjects: 40
Study 35202009 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume regimen (1.0 to 1.5 L of MoviPrep)
Number of subjects: 40
Study 32539588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause reading intervention
Number of subjects: 150
Study 32539588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic reading intervention
Number of subjects: 150
Study 32539588 — intervention group
Group type: COMPARATOR
Intervention: Active shared reading control condition
Number of subjects: 150
Study 35162319 — intervention group
Group type: COMPARATOR
Intervention: Not specified; the study is a cross-sectional survey and part of a phase III wait-listed cluster randomised controlled trial.
Number of subjects: 0
Study 33225724 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - four individual face-to-face sessions per month
Number of subjects: 60
Study 33225724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motivational interviewing)
Number of subjects: 60
Study 33225724 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 60
Study 33523688 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Selection (described as 'friends')
Number of subjects: 280
Study 33523688 — intervention group
Group type: COMPARATOR
Intervention: Object Selection (described as 'toys')
Number of subjects: 280
Study 33523688 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Selection of a numerically rare group
Number of subjects: 280
Study 33523688 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Selection with active selection of friends
Number of subjects: 280
Study 33523688 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Selection of a rare selected group
Number of subjects: 280
Study 35084374 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress from palpitations
Number of subjects: 293
Study 33293672 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
Number of subjects: 713
Study 33293672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 37143013 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention (PACINPAT)
Number of subjects: 95
Study 32985122 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC/DTG
Number of subjects: 91
Study 32985122 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/NNRTI
Number of subjects: 91
Study 32928717 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraflex Cruz stent
Number of subjects: 1550
Study 32928717 — intervention group
Group type: COMPARATOR
Intervention: SYNERGY stent
Number of subjects: 1550
Study 34515056 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin solution (HAS)
Number of subjects: 1508
Study 34515056 — intervention group
Group type: COMPARATOR
Intervention: 4% human albumin solution (HAS)
Number of subjects: 1508
Study 33078978 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles
Number of subjects: 1381
Study 33078978 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor
Number of subjects: 1381
Study 34975146 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide extended release once-weekly (ExQW)
Number of subjects: 42
Study 34975146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 36258233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 37
Study 34190361 — intervention group
Group type: EXPERIMENTAL
Intervention: romosozumab 210 mg monthly for 12 months
Number of subjects: 4093
Study 34190361 — intervention group
Group type: COMPARATOR
Intervention: alendronate 70 mg weekly for 12 months
Number of subjects: 4093
Study 36173985 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD with CO2 insufflation
Number of subjects: 30
Study 36173985 — intervention group
Group type: COMPARATOR
Intervention: Pre-EGD AUS
Number of subjects: 30
Study 34610729 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation immediately before resistance training
Number of subjects: 10
Study 34610729 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation immediately after resistance training
Number of subjects: 10
Study 34610729 — intervention group
Group type: COMPARATOR
Intervention: Placebo immediately before resistance training
Number of subjects: 10
Study 34610729 — intervention group
Group type: COMPARATOR
Intervention: Placebo immediately after resistance training
Number of subjects: 10
Study 32379269 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) daily for 7 days
Number of subjects: 30
Study 32379269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35514277 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises with a Pilates ball (IG)
Number of subjects: 62
Study 35514277 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 62
Study 33353735 — intervention group
Group type: COMPARATOR
Intervention: Flowable SFRC as luting-core material with individually-made FRC post (Group C3)
Number of subjects: 170
Study 33353735 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable SFRC (Group C1)
Number of subjects: 170
Study 33353735 — intervention group
Group type: EXPERIMENTAL
Intervention: Other groups (A1-A2, B1-B2, C2, C4)
Number of subjects: 170
Study 34557093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary physician-pharmacist medication review
Number of subjects: 93
Study 32023233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining TKA
Number of subjects: 50
Study 32023233 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-retaining TKA
Number of subjects: 50
Study 36333791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilizing to toilet
Number of subjects: 116
Study 36333791 — intervention group
Group type: COMPARATOR
Intervention: Bedpan use
Number of subjects: 116
Study 36333791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilizing to toilet after crossover
Number of subjects: 116
Study 36333791 — intervention group
Group type: COMPARATOR
Intervention: Bedpan use after crossover
Number of subjects: 116
Study 33667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) 150 mg/kg, ad libitum feeding
Number of subjects: 378
Study 33667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) 150 mg/kg, pair-fed
Number of subjects: 378
Study 33667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) free-fed
Number of subjects: 378
Study 33667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) ad libitum feeding
Number of subjects: 378
Study 33667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 378
Study 33667870 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 378
Study 32490838 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART‐COPD intervention (n=19)
Number of subjects: 30
Study 32490838 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 30
Study 36055582 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and retention strategies
Number of subjects: 382
Study 36055582 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention at 3 months
Number of subjects: 382
Study 36055582 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention at 6 months (primary endpoint)
Number of subjects: 382